A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC.
Dietlein F, et al. Among authors: sprick mr.
Cell. 2015 Jul 2;162(1):146-59. doi: 10.1016/j.cell.2015.05.053.
Cell. 2015.
PMID: 26140595
Free article.